Navigation

BLOG ARCHIVES

Category: Gene Therapy Investing

3 Gene Therapy Companies Powering a Revolution in Rare Disease Cures

By AGT | Jan 20, 2021

Contributing Author: Gina Hagler Gene therapy companies are powering a revolution in rare disease cures by offering treatments that target the genetic cause of the disease. Rather than try different combinations of chemicals to create a small-molecule treatment as is the case with traditional pharmaceuticals, gene therapy uses genetic material in drug development to repair or replace the genetic cause…. [Read More]

5 Reasons Gene Therapy Companies are Vital to the Future of Biopharma

By AGT | Jan 20, 2021

Contributing Author: Gina Hagler Pharmaceutical companies have been developing therapies to treat or prevent disease since the end of the 19th century. Chemical compounds are used to create these drugs and medications. The resulting small-molecule drugs – think aspirin – are ingested, metabolized and circulate through the blood. Because it’s not possible to target these drugs, they have a systemic… [Read More]

7 Cell Therapy Companies in Maryland Helping to Revolutionize Drug Discovery: The Latest News

By AGT | Dec 29, 2020

Contributing Author: Gina Hagler Maryland is home to one of the largest life science clusters in the United States with more than 500 biotech companies. In addition to several state-of-the-art labs, Maryland is home to the NIH in Bethesda. Research opportunities, as well as BS and MS degree programs, are offered at Johns Hopkins in Baltimore and the University of Maryland… [Read More]

The Death of the Regulatory Barrier to Better Medicine

By AGT | Jul 7, 2020

Written by Jeff Galvin, CEO of American Gene Technologies The birth of high-value therapeutics and cures Does the development of effective drugs have to be incredibly expensive?  Maybe not anymore. There is a new type of drug development emerging: Gene Therapy. The hallmark of gene therapy is the ability to edit or modify the drivers of disease at the most fundamental… [Read More]

What Impact Did the Stock Market Crash Have on Biotech Stocks?

By AGT | May 13, 2020

Contributing Author John Vandermosten, Senior Biotechnology Analyst Examining events of the past can give us a sense of what to expect in the periods ahead. And despite the omnipresent warning that “past performance is not indicative of future results” we will share some historical trends on biotech performance surrounding economic contractions that may prove useful in the current environment. The pandemic… [Read More]

12 Coronavirus Stocks To Watch As The Race For A Coronavirus Vaccine and Treatment Continues

By AGT | Mar 30, 2020

Contributing Author John Vandermosten, Senior Biotechnology Analyst Over the last two months nothing has dominated the news as extensively as the coronavirus pandemic which as of March 26th has infected 463,000 people and caused almost 21,000 deaths in in almost every country around the world.  The impact from the spread of the virus has impacted not only the health of those… [Read More]

Gene Therapy M&A: Best Prospects 2020

By AGT | Mar 18, 2020

Contributing Author John Vandermosten, Senior Biotechnology Analyst As we enter the twelfth year of an economic expansion, deal activity remains one of the primary ways for large companies to expand both the top and bottom line. One of the dominant industries in the merger and acquisition space has been biotech and life sciences. With scientific breakthroughs coming at an accelerating… [Read More]

Gene Therapy Companies in Maryland

Gene Therapy Companies in Maryland

By AGT | Aug 8, 2019

Maryland is home to one of the largest life science clusters in the nation. According to the Maryland Department of Commerce, the State has nearly 2,300 life science companies and 476 private research and development biotechnology firms (NAICS 541714), which represents 5.3% of this U.S. industry. Some of the nation’s most important research occurs within Maryland at National Institute of… [Read More]

Gene Therapy Stocks 2019

Gene Therapy Stocks 2019

By AGT | Jun 12, 2019

Why has gene therapy become so significant within the last five years? While it is not well-known, the genes we are born with can be flawed and there are >7000 genetic diseases in the world today. These genetic diseases result in the loss of critical enzymes or proteins in our bodies. Loss of normal proteins and enzymes can lead to… [Read More]

Acquisition of Celgene – Medicine is Changing

Acquisition of Celgene – Medicine is Changing

By AGT | Mar 11, 2019

On January 3rd, Bristol-Myers Squibb announced its agreement to acquire Celgene for approximately $74 billion. This merger is a sign of change for pharmaceutical companies. Like a military planning for the previous war, corporations are always planning for the past rather than the future. In the past, pharmaceutical companies could simply stay big, block market access to smaller companies, and… [Read More]

Why Invest in an HIV Gene Therapy Cure

Why Invest in an HIV Gene Therapy Cure?

By AGT | Dec 27, 2018

Research and innovation to cure HIV is developing fast. American Gene Technologies (AGT) is emerging as a leader in the field with their first functional cure for HIV, expected to enter clinical trials in 2019. Unlike the current antiretrovirals used in HIV treatment, AGT’s solution is a one-time intervention that eliminates the need for ongoing antiretrovirals, as well as their… [Read More]

The Next Generation of Gene Therapy Companies

The Next Generation of Gene Therapy Companies

By AGT | Dec 18, 2018

The future of medicine is bright. This year brought several first in class technologies over the finish line. The underpinning of these radical medical developments is the understanding of how human genes can be modified to cure diseases and save lives. The technology which captured the most attention this year is CAR-T therapy. A CAR-T therapy consists of the infusion… [Read More]

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about AGT!

Mailchimp sidebar

Follow AGT on Social Media